15:26 , May 9, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Serum levels of miR-940, miR-451a, miR-16-5p and miR-17-3p could help predict response to Herceptin trastuzumab in HER2 (EGFR2; ErbB2; neu)-positive metastatic breast cancer patients. In 283 HER2-positive metastatic breast cancer patients receiving...
20:51 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample, cell culture and mouse studies suggest blocking the interaction of miR-16 and TYRP1 mRNA could help treat melanoma. In melanoma patients, the absence of the low-expressing TYRP1-A allele in tumors was...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

TargomiRs: Phase I started

EnGeneIC and the Asbestos Diseases Research Institute began the open-label, dose-escalation, Australian Phase I MesomiR-1 trial to evaluate IV TargomiRs in up to 22 patients with MPM who failed to respond to standard of care...
07:00 , Apr 10, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Cancer Chronic lymphocytic leukemia (CLL) miR-15a; miR-16-1 A study of a leukemia cell line and primary samples from CLL patients identified a coexpressed gene signature that could be useful for diagnosing...